Emergence of drug resistant influenza viruses more common than previously thought

Results of a small study from Japan in this week’s issue of THE LANCET suggest that the emergence of influenza viruses which are resistant to a widely used influenza drug may be more common than previously thought.

A drug class called neuraminidase inhibitors are an effective option for treating influenza; the drugs act by blocking an enzyme which usually allows the influenza virus to escape and infect other cells. The neuraminidase inhibitor oseltamivir is widely used, although no research has established the risk of the emergence of viruses resistant to this drug during clinical use.

Yoshihiro Kawaoka from the University of Tokyo, Japan and colleagues investigated oseltamivir resistance in a group of children treated for influenza. Children, being more susceptible to influenza than adults, are thought to be a useful group to study as they could provide a model similar to that of a general population during a flu pandemic.

Influenza A viruses (H3N2) collected from 50 Japanese children before and during treatment with oseltamivir were analysed. Neuraminidase mutations were found in viruses from nine patients (18%). Oseltamivir-resistant viruses were first detected 4 days after the start of treatment and on each successive day of the study.

Dr Kawaoka comments: “Oseltamivir-resistant mutants in children being treated for influenza with oseltamivir arise more frequently than previously reported. Furthermore, children can be a source of viral transmission, even after 5 days of treatment with oseltamivir”.

In an accompanying commentary, Anne Moscona from Mount Sinai School of Medicine, New York, USA concludes: “We need more information on the emergence of resistance, especially in oseltamivir-treated patients, and we urgently need to know whether resistant variants, such as those identified in Kiso’s study, are transmissible. The development of the neuraminidase inhibitors has been a true success story: protein structural analysis directly applied to preventing and treating a major infectious threat. Let us take Kiso and colleagues’ study as an energising mandate to learn more about the incidence and mechanisms of resistance to the neuraminidase inhibitors, so that appropriate strategies can be developed for their use during the next pandemic”.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
H5N1 influenza outbreak in Texas dairy cattle sparks multi-species transmission concerns